5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.

Journal Article (Clinical Trial;Journal Article)

A phase II trial of 5-fluorouracil (5-FU) [250-450 mg/m2/day x 5 days as an intravenous (IV) bolus] combined with calcium leucovorin (500 mg/m2/day x 5 1/2 days by continuous IV infusion) administered on a 28-day schedule was performed in 15 patients with advanced hepatocellular carcinoma. The median age was 58 years; performance status ranged from 50 to 100%. Of 15 evaluable patients, 1 (7%) had a partial response lasting 2.4 months; 8 (53%) had stable disease with a median duration of 5.7 months; and 6 (40%) had progressive disease with a median time to progression of 2.7 months. Median survival was 3.8 months. Treatment with 5-FU and calcium leucovorin was moderately well tolerated; 9% of the treatment courses were complicated by grade 3 or 4 hematological toxicity, and 10% of the courses were complicated by grade 3 or 4 gastrointestinal toxicity. Despite the efficacy of the combination of 5-FU and leucovorin in advanced colorectal cancer, our results document the general resistance of hepatocellular carcinoma to modulated 5-FU.

Full Text

Duke Authors

Cited Authors

  • Tetef, M; Doroshow, J; Akman, S; Coluzzi, P; Leong, L; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G

Published Date

  • 1995

Published In

Volume / Issue

  • 13 / 5

Start / End Page

  • 460 - 463

PubMed ID

  • 7552810

International Standard Serial Number (ISSN)

  • 0735-7907

Digital Object Identifier (DOI)

  • 10.3109/07357909509024907


  • eng

Conference Location

  • England